AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02581241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tilt table
Description: Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital
Study NCT02608684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV solution
Study NCT02608684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine IV solution
Study NCT02608684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin IV solution
Study NCT03531112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appetite Awareness Treatment + Lifestyle Modification
Description: The AAT + LM intervention includes 16 60-90 minute group sessions to enable participants to be able to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. All sessions involve didactic training, review of self-monitoring of eating episodes, interactive activities, and homework assignments to enable participants to practice learned skills. Participants will be provided a workbook, which will include session content, and self-monitoring forms.
Study NCT02911168 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal Intercostal Block
Description: After identifying the correct intercostal space, the ultrasound probe will be moved medially to identify the transverse processes, then again laterally from the transverse processes to rest over the ribs so as to obtain the best view of ribs and pleura. A 10cm, 21G needle will be inserted in-plane at the caudal border of the probe. An attempt will be made to keep the needle tip and the target injection position (just under the internal intercostal membrane (IIM)) in view. Correct needle tip placement will be demonstrated by depression of the pleura/endothoracic fascia upon local anesthetic injection and by lack of retrograde spread of LA over the muscles or the ribs. The LA will be injected in 4 cc aliquots after negative aspiration of air, CSF and blood.
Study NCT02911168 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Block
Description: After identifying the correct intercostal space, the ultrasound probe will be placed between the adjacent transverse processes in a longitudinal/parasagittal plane measuring 2.5cm from the midline. The best possible view of the transverse processes, the superior costotransverse ligament and pleura will be obtained. An attempt will be made to keep the needle tip and the target injection position (immediately beneath the costotransverse ligament) in view. Correct placement of the needle tip will be demonstrated by depression of the pleura upon injection of local anesthetic and by lack of retrograde spread of LA over the muscles or transverse processes. The LA will be injected in 4 cc aliquots after confirming negative aspiration of air, CSF and blood.
Study NCT04093102 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: biomarkers
Description: bio-markers testing will be made to all suspected OSA patients(CRP, Hba1C,uric acid, ESR, plasma fibrinogen, pentraxin3), and to control cases.
Study NCT00890123 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omegaven-IV FO
Description: Will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
Study NCT02044640 — intervention group
Intervention type: PROCEDURE
Intervention: Appendectomy
Study NCT01987453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: Tablet(s) administered orally once daily
Study NCT01987453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)~Participants in the LDV/SOF+RBV 24 weeks group will dose adjust RBV according to hemoglobin and renal status as stated in the RBV package insert.
Study NCT03598686 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OraQuick
Description: Most trials assessing oral HIVST make use of OraQuick® (OraQuick ADVANCE HIV I/II test kits, packaged for self-use), an oral-fluid rapid self-test. OraQuick® is a 2nd generation serology assay with a sensitivity of 99.3% (95%CI; 98.4%, 99.7%) and a specificity of 99.8% (95%CI; 99.6%, 99.9%). In a pilot study with 59 participants conducted in Lesotho in 2015 more than 90% of the participants found utilization of OraQuick® easy, and trusted the results of the self-test kit. The WHO recently has announced that OraQuick becomes the first prequalified HIV self-test, in order to improve diagnosis in low-resourced health systems and in countries where stigma prevents people from getting tested. Therefore, OraQuick® is now available in Lesotho for as little as 2 USD per test kit.
Study NCT00880243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF
Description: Randomization 1: GM-CSF (5micogram/Kg/d) versus no GM-CSF during induction chemotherapy and all consolidation courses.~Randomiization 2: Consolidation high dose AraC versus consolidation EMA
Study NCT00880243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Randomization 1: GM-CSF (5micogram/Kg/d) versus no GM-CSF during induction chemotherapy and all consolidation courses.~Randomiization 2: Consolidation high dose AraC versus consolidation EMA
Study NCT02824653 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: Allogenic Human Bone Marrow Mesenchymal Stem Cells (ex-vivo expanded in pooled human platelet lysate)
Study NCT03485378 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: Stereotactic ablative radiotherapy for early non-small cell lung cancer and interstitial lung disease
Study NCT00809718 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Raltegravir and rifapentine
Description: Period 1- Raltegravir 400 mg q12h by mouth for 4 days~Period 2- Rifapentine 900 mg taken by mouth once per week for 3 doses and raltegravir 400 mg q12h by mouth for 4 days~Period 3- Rifapentine 600 mg taken by mouth once daily for 5 of 7 days per week for 10 doses and raltegravir 400 mg q12h by mouth for 4 days
Study NCT02018718 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Study NCT02853617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV0328 - Cohort 1
Description: Cohort 1 will receive 15 µg to be given as an IM injection
Study NCT02853617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV0328 - Cohort 2
Description: Cohort 2 will receive 30 µg to be given as an IM injection
Study NCT02853617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV0328 - Cohort 3
Description: Cohort 3 will receive 75 µg to be given as an IM injection
Study NCT02853617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV0328 - Cohort 4
Description: Cohort 4 will receive 150 µg to be given as an IM injection
Study NCT01597596 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alglucosidase alfa
Description: Intravenous (IV) infusion of alglucosidase alfa (4000 L material) 20 mg/kg every other week (QOW)
Study NCT01597596 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: alglucosidase alfa
Description: IV infusion of alglucosidase alfa (160 L material) 20 mg/kg QOW.
Study NCT01744106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pseudoephedrine hydrochloride 30 mg tablets
Study NCT01744106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Study NCT04371159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Velieve U.S.
Description: The Velieve U.S. is a home use, in-vitro diagnostic (IVD) device. The device is used for the semi-quantitative detection of blood and leukocytes, and the qualitative detection of nitrites in urine.
Study NCT03714958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201
Description: Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study NCT03714958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study NCT04398927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: Systemic Chemotherapy (Oxaliplatin，5-fluorouracil and Irinotecan)
Study NCT04398927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab
Study NCT03304158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FCHV visit
Description: FCHVs will visit selected households 3 times a year for providing health promotion messages and measure the blood glucose
Study NCT04563143 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Novel DBS Stimulation
Description: Stimulation patterns will vary from the standard therapeutic approach in terms of frequency, contact location, and/or temporal pattern.
Study NCT00217607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT02804113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supera Peripheral Stent System
Study NCT03013803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutricomp Drink Plus Fibre
Study NCT01209689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Study NCT01209689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02393378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Namilumab
Description: Namilumab injection
Study NCT02393378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab SC injection
Study NCT02393378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate tablet
Study NCT02393378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate tablet
Study NCT02393378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Folic Acid Tablet
Study NCT02393378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic Acid Tablet
Study NCT04598802 — intervention group
Intervention type: DEVICE
Intervention: covered stent
Description: atherosclerotic aorto-iliac aneurysm
Study NCT03714672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol/Diclofenac 50/50
Description: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
Study NCT03714672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol/Diclofenac 25/25
Description: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
Study NCT03714672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol 50
Description: Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.
Study NCT03714672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac 50
Description: Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
Study NCT04179669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI306
Description: Administered by subcutaneous injection
Study NCT04179669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered by subcutaneous injection
Study NCT04349397 — intervention group
Intervention type: BEHAVIORAL
Intervention: Medication Tracking Form
Description: Parents will complete medication tracking form for 5 days after child's surgery. They will track medications administered, pain scores, nausea and vomiting
Study NCT04377893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eye gaze AT intervention
Description: The eye-gaze AT intervention includes eye-gaze AT and service delivery to support the participants using this technology in daily life. The Tobii PCEye Mini (Tobii, Danderyd, Sweden) and specialized software are applied with adaptation to meet each child's individual needs.~To ensure the consistency of service delivery, two-day courses are conducted before the intervention. The participant's teachers or parents are invited as the main interventionist to facilitate the child's usage of eye-gaze AT in daily life under team support. The service delivery involves parents in joint goal-setting, planning, and jointly review the progress of the usage of eye-gaze AT as a family-centered practice. Individual meetings and individual supports are provided during intervention periods. The collaborative team will perform biweekly follow-up contacts during intervention periods.~The researcher will conduct the fidelity checklist every month to determine the extent of treatment integrity.
Study NCT00741182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPTH(1-34)
Description: Injection of 20 micrograms per day in eight weeks
Study NCT01628666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Incremental
Description: Single dose of Cefazolin and Vancomycin preoperatively, bacitracin wash and cefalexin post operative.
Study NCT01628666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional
Description: Cefazolin preoperative
Study NCT02268357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol
Description: Oral propranolol capsules
Study NCT02268357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Oral propranolol capsules
Study NCT03807856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran Etexilate Mesylate
Description: Dabigatran 150mg BID for 3 days
Study NCT03807856 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Daily vital signs, lab work and one outpatient clinic visit
Study NCT04748198 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracorneal ring segment implantation
Description: Surgical procedure for keratoconus treatment. A tunnel is created in the corneal stroma with femtosecond laser and ring segments are implanted in the corneal stroma
Study NCT03077412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily
Study NCT03077412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily
Study NCT00055757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally
Study NCT00055757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00055757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00055757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03478098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low GI mealtest
Description: Meal with low glycaemic index (GI) is consumed over 20 min
Study NCT03478098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low GI mealtest and subsequent exercise
Description: Meal with low glycaemic index (GI) is consumed over 20 min and the subject postprandially exercises for 30 min
Study NCT03478098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High GI mealtest
Description: Meal with high glycaemic index (GI) is consumed over 20 min
Study NCT03478098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High GI mealtest and subsequent exercise
Description: Meal with high glycaemic index (GI) is consumed over 20 min and the subject postprandially exercises for 30 min
Study NCT02549872 — intervention group
Intervention type: OTHER
Intervention: This is not an intervention study
Description: This study is based on the retrospective analysis of linked electronic health records.
Study NCT03208647 — intervention group
Intervention type: OTHER
Intervention: AA or not
Description: to study their risk factors
Study NCT03317184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periumbilical incision
Description: A periumbilical incision is made at the abdominal midline for hand-assisted laparoscopic donor nephrectomy.
Study NCT03317184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pfannenstiel incision
Description: Pfannenstiel incision is made as a slightly curved horizontal line just above the pubic symphysis for hand-assisted laparoscopic donor nephrectomy.
Study NCT02911584 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic procedure
Study NCT04381754 — intervention group
Intervention type: DEVICE
Intervention: Passeo-18 Lux
Description: Patients with significant inflow or outflow stenosis between the anastomosis to the axillary-subclavian vein junction, as defined by the insertion of the cephalic vein, who had undergone fistuloplasty with Passeo-18 Lux
Study NCT00874094 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich fibrin matrix
Description: 0-2 cc of autologous platelet rich fibrin matrix injected intra and subdermally to effect nasolabial fold.
Study NCT01856959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: 2ml of 7.5% solution of isotonic magnesium heptahydrate, 150 mg
Study NCT01856959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium sulfate & albuterol
Description: 0.5ml of albuterol mixed with 2ml of isotonic magnesium sulfate,150mg+2.5mg
Study NCT01856959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: 0.5ml of albuterol mixed with 1.5cc of normal saline, 2.5 mg
Study NCT03976219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECAPS Closed Loop SCS
Description: The purpose of this study is to determine the feasibility of recording evoked compound action potentials (ECAPs) and somatosensory evoked potentials (SSEPs) from the spinal cord (SC) and Dorsal root ganglions (DRG), and their suitability as feedback signals.
Study NCT01110902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agomelatine (AGO178C)
Study NCT01110902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04723277 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tealeaf-Mansik Swasta (Tealeaf)
Description: Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family. Teachers receive ongoing supervision and support from the intervention team including monthly site visits supplemented by monthly and as-needed telephone discussions.
Study NCT04723277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tealeaf-Mansik Swasta (Tealeaf)
Description: Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family. Teachers receive ongoing supervision and support from the intervention team including monthly site visits supplemented by monthly and as-needed telephone discussions.
Study NCT04723277 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: Enhanced Usual Care (EUC) is a less intensive version of the Tealeaf intervention. The EUC service package has been designed to be the most intensive form of care that could be envisioned as viable in the study setting in the foreseeable future without a significant increase in resource investment.
Study NCT04723277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care (EUC)
Description: Enhanced Usual Care (EUC) is a less intensive version of the Tealeaf intervention. The EUC service package has been designed to be the most intensive form of care that could be envisioned as viable in the study setting in the foreseeable future without a significant increase in resource investment.
Study NCT04731545 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant placement
Description: Minimally traumatic tooth extraction, immediate implant placement and hard tissue grafting. loading after 3 months.